MSD’s Keytruda has significantly increased overall survival in patients with lung cancer expressing any level of PD-L1 when used as monotherapy in the first-line setting, potentially significantly increasing the drug’s treatment scope.
Read More
Patients with a certain form of lung cancer will, for the first time, be able to get treatment with Merck & Co’s immunotherapy Keytruda as a first-line of attack instead of chemotherapy, following a green light from European regulators in this setting.
Read More
Merck & Co has agreed to pay Bristol-Myers Squibb and Ono Pharmaceutical Co $625 million plus royalties to lay to rest a global patent battle relating to cancer immunotherapy Keytruda.
Read More
